Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Updates in HR-Positive mBCa

Erika Hamilton • 2 Jun 2019
ASCO 2019
Breast Cancer General Ribociclib Tamoxifen
MONALEESA-7

Erika Hamilton, MD, of the Sarah Cannon Research Institute, Nashville, TN, discusses trial updates and drug targets for hormone receptor-positive metastatic breast cancer (mBCa). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Erika Hamilton

1:05
CAMBRIA 1: camizestrant ER+/HER2- early breast cancer
Erika Hamilton • 12 Dec 2023
2:03
The landscape of oral SERDs and their potential in ER+ breast cancer
Erika Hamilton • 12 Dec 2023
1:56
Vepdegestrant + palbociclib in ER+ metastatic breast cancer: Phase Ib trial results
Erika Hamilton • 12 Dec 2023
1:08
Non-adherence in breast cancer treatment
Erika Hamilton • 20 Oct 2023

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals